MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Has $34.58 Million Stock Holdings in Kenvue Inc. (NYSE:KVUE)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH reduced its stake in shares of Kenvue Inc. (NYSE:KVUE) by 12.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,632,584 shares of the company’s stock after selling 224,319 shares during the period. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH owned approximately 0.09% of Kenvue worth $34,578,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Grove Bank & Trust boosted its stake in shares of Kenvue by 438.4% during the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock worth $25,000 after buying an additional 947 shares during the last quarter. Riverview Trust Co bought a new stake in Kenvue during the third quarter worth about $30,000. Fortitude Family Office LLC boosted its position in Kenvue by 106.6% during the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock valued at $32,000 after purchasing an additional 777 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in Kenvue in the third quarter valued at approximately $35,000. Finally, Versant Capital Management Inc increased its position in shares of Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after purchasing an additional 1,441 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Barclays cut their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and upped their target price for the company from $21.00 to $26.00 in a research report on Monday, January 6th. Finally, Bank of America lifted their price target on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $23.08.

Kenvue Stock Performance

KVUE opened at $20.75 on Friday. The firm has a market cap of $39.77 billion, a P/E ratio of 37.72, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The business’s fifty day moving average is $22.26 and its 200-day moving average is $21.74. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same period last year, the firm earned $0.31 EPS. The business’s quarterly revenue was down .4% compared to the same quarter last year. Sell-side analysts expect that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.95%. Kenvue’s dividend payout ratio is currently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.